...
首页> 外文期刊>Journal of Antimicrobial Chemotherapy >Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis
【24h】

Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis

机译:通过实时PCR和熔解曲线分析直接在临床标本中检测到法国的肺炎支原体大环内酯类药物耐药性增加

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives Mycoplasma pneumoniae is a common aetiological agent of community-acquired respiratory tract infections for which macrolides are the treatment of choice. In France, only two macrolide-resistant isolates were reported in 1999. In contrast, several recent data reported that macrolide-resistant M. pneumoniae isolates have been spreading since 2000 in Japan. Mutations A2058G (Escherichia coli numbering), A2058C, A2059G, A2062G, C2611A and C2611G in domain V of the 23S rRNA gene were associated in vivo or in vitro with this resistance. The aim of this study was to determine whether macrolide resistance of M. pneumoniae is emerging in France.
机译:目的肺炎支原体是社区获得性呼吸道感染的常见病原体,大环内酯类药物是治疗的选择。在法国,1999年仅报告了两种对大环内酯类耐药的菌株。相反,最近的一些数据报道,自2000年以来,耐大环内酯类肺炎支原体的分离株已在日本传播。 23S rRNA基因结构域V中的突变A2058G(大肠杆菌编号),A2058C,A2059G,A2062G,C2611A和C2611G在体内或体外与这种抗性相关。这项研究的目的是确定法国是否出现了肺炎支原体的大环内酯类耐药性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号